COVID-19 Vaccines Deemed Safe for Patients With Solid Tumors
Patients with solid tumors do not appear to have an increased risk of side effects from COVID-19 vaccination, according to a systematic review.
Patients with solid tumors do not appear to have an increased risk of side effects from COVID-19 vaccination, according to a systematic review.
Several factors influenced the likelihood of COVID-19 vaccination among patients with cancer who already had COVID-19, a new study suggests.
Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.
The FDA has authorized use of the bivalent Pfizer-BioNTech COVID-19 vaccine as a booster dose for children 6 months through 4 years of age.
The mean time to resolution of axillary lymphadenopathy after a COVID-19 vaccine booster is 102 days, according to a study.
Patients with COVID-19 may experience viral and symptom rebound more often than previously reported, a study suggests.
Nearly one-quarter of parents surveyed knowingly exposed others to their child when the child had or may have had COVID-19.
Methods to prevent and treat COVID-19 in cancer patients have had to evolve alongside the SARS-CoV-2 virus.
Screening for breast, cervical, and prostate cancer did not return to pre-pandemic levels in 2021 in the United States, a study suggests.
Four volatile organic compounds differentiated between COVID-19 and non-COVID illness with 90.2% accuracy.